LTIP227A - Nauji farmakologiškai aktyvūs katecholio dariniai - Google Patents

Nauji farmakologiškai aktyvūs katecholio dariniai

Info

Publication number
LTIP227A
LTIP227A LTIP227A LTIP227A LTIP227A LT IP227 A LTIP227 A LT IP227A LT IP227 A LTIP227 A LT IP227A LT IP227 A LTIP227 A LT IP227A LT IP227 A LTIP227 A LT IP227A
Authority
LT
Lithuania
Prior art keywords
pharmacologically active
catechol derivatives
new pharmacologically
active catechol
new
Prior art date
Application number
LTIP227A
Other languages
English (en)
Inventor
Johannes Reijo Backstrom
Erkki Honkanen
Britt Inge LINDEN
Aarne Olavi Erkki NISSINEN
Aino Pippuri
Pentti Pohto
Tapio Korkolainen
Original Assignee
Orion-Yhtymae Oy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB909009565A external-priority patent/GB9009565D0/en
Priority claimed from GB919101563A external-priority patent/GB9101563D0/en
Application filed by Orion-Yhtymae Oy filed Critical Orion-Yhtymae Oy
Publication of LTIP227A publication Critical patent/LTIP227A/lt
Publication of LT3137B publication Critical patent/LT3137B/lt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/96—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/38—One sulfur atom
    • C07D239/40—One sulfur atom as doubly bound sulfur atom or as unsubstituted mercapto radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/60—Three or more oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/60—Three or more oxygen or sulfur atoms
    • C07D239/62—Barbituric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/46—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Vascular Medicine (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Formulę (1) atitinkantys katecholio junginiai, kurioje R1 reiškia tokį elektriškai neigiamą pakaitą, kaip nitro-, halogeno ar ciano-grupė, o R2 yra grupė, pasirinkta iš (1a) ir (1b), kur R reiškia vandenilį arba alkilo, cikloalkilo ar arilo grupę, kurioje X1, X2, Y ir Z nepriklausomai reiškia deguonį ar sierą, priklausančius NR, kur R gali turėti aukščiau nurodytas reikšmes ir farmaciškai priimtinos jų druskos bei esterai, naudingi dėl lipidų peroksidacijos atsiradusio audinių pakenkimo profilaktikai ir gydymui.
LTIP227A 1990-04-27 1992-11-17 New pharmacologically active catechol derivatives LT3137B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB909009565A GB9009565D0 (en) 1990-04-27 1990-04-27 New pharmacologically active catechol derivatives
GB919101563A GB9101563D0 (en) 1991-01-24 1991-01-24 New pharmacologically active catechol derivatives
PCT/FI1991/000124 WO1991017151A1 (en) 1990-04-27 1991-04-26 New pharmacologically active catechol derivatives

Publications (2)

Publication Number Publication Date
LTIP227A true LTIP227A (lt) 1994-08-25
LT3137B LT3137B (en) 1995-01-31

Family

ID=26297011

Family Applications (1)

Application Number Title Priority Date Filing Date
LTIP227A LT3137B (en) 1990-04-27 1992-11-17 New pharmacologically active catechol derivatives

Country Status (17)

Country Link
US (3) US5362733A (lt)
EP (1) EP0526598B1 (lt)
JP (1) JP2972377B2 (lt)
KR (1) KR100207144B1 (lt)
AT (1) ATE146462T1 (lt)
AU (1) AU646464B2 (lt)
CA (1) CA2080917C (lt)
DE (1) DE69123738T2 (lt)
FI (1) FI95129C (lt)
HU (1) HU214872B (lt)
IE (1) IE911430A1 (lt)
LT (1) LT3137B (lt)
LV (1) LV10097B (lt)
NO (1) NO301928B1 (lt)
PL (1) PL166269B1 (lt)
PT (1) PT97507B (lt)
WO (1) WO1991017151A1 (lt)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR19980701588A (ko) * 1995-01-23 1998-05-15 피터 쥐. 스트링거 다발성 경화증의 치료 방법(Method for Treating Multiple Sclerosis)
WO1998033777A1 (en) * 1997-01-31 1998-08-06 Shionogi & Co., Ltd. Compounds having metalloprotease inhibitory activity
WO1998039967A1 (en) * 1997-03-12 1998-09-17 The General Hospital Corporation A method for treating or preventing alzheimer's disease
US20040058873A1 (en) * 1998-03-12 2004-03-25 Esmond Robert W. Method for treating or preventing Alzheimer's disease
US6191154B1 (en) 1998-11-27 2001-02-20 Case Western Reserve University Compositions and methods for the treatment of Alzheimer's disease, central nervous system injury, and inflammatory diseases
WO2001030771A1 (en) * 1999-10-28 2001-05-03 Kyowa Hakko Kogyo Co., Ltd. Thiazolidinedione derivatives
WO2002053155A1 (en) * 2000-12-30 2002-07-11 Geron Corporation Telomerase inhibitor
WO2003009807A2 (en) * 2001-07-23 2003-02-06 Galileo Laboratories, Inc. Cytoprotective compounds, pharmaceutical and cosmetic formulations, and methods
US6679051B1 (en) * 2002-07-31 2004-01-20 Ford Global Technologies, Llc Diesel engine system for use with emission control device
EP2295418A1 (en) 2003-11-21 2011-03-16 Actelion Pharmaceuticals Ltd. 5-(benz-(z)-ylidene)-thiazolidin-4-one derivatives as immunosuppressant agents
USRE43833E1 (en) 2003-11-21 2012-11-27 Actelion Pharmaceuticals Ltd. Thiazolidin-4-one derivatives
WO2007098010A2 (en) * 2006-02-17 2007-08-30 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Improved low molecular weight myc-max inhibitors
DK2094676T3 (da) * 2006-11-23 2013-06-10 Actelion Pharmaceuticals Ltd Ny fremgangsmåde til fremstillingen af 2-iminothiazolidin-4-on-derivater
US8912340B2 (en) 2006-11-23 2014-12-16 Actelion Pharmaceuticals Ltd. Process for the preparation of 2-imino-thiazolidin-4-one derivatives
FR2919608B1 (fr) * 2007-08-01 2012-10-05 Univ Rennes Derives d'imidazolones,procede de preparation et applications biologiques
CN102159203A (zh) * 2008-07-23 2011-08-17 麻省理工学院 组蛋白脱乙酰酶1(hdac1)的活化防范dna损伤和增加神经元存活
KR101411838B1 (ko) 2011-02-09 2014-06-27 부산대학교 산학협력단 피부미백, 항산화 및 ｐｐａｒ 활성을 갖는 신규 화합물 및 이의 의학적 용도
EP3483150A1 (en) 2011-07-22 2019-05-15 Massachusetts Institute Of Technology Activators of class 1 histone deacetylases (hdacs) and uses thereof
SI2885266T1 (sl) 2012-08-17 2020-10-30 Actelion Pharmaceuticals Ltd Postopek za pripravo (2Z,5Z)-5-(3-kloro-4-((R)-2,3-dihidroksipropoksi) benziliden)-2-(propilimino)-3-(O-tolil)tiazolidin-4-on in v omenjenem postopku uporabljena vmesna spojina
KR102516038B1 (ko) * 2016-04-05 2023-03-31 이뮨 센서, 엘엘씨 cGAS 길항제 화합물
JPWO2022163843A1 (lt) * 2021-02-01 2022-08-04

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1038050B (de) * 1955-11-17 1958-09-04 Farmaceutici Italia S A Soc Verfahren zur Herstellung von 5-(3', 4'-Dioxybenzyliden)-Derivaten heterocyclischer Verbindungen
GB1434074A (en) * 1972-06-16 1976-04-28 Canada Packers Ltd Antiviral compositions comprising hydantoin derivatives
US4264617A (en) * 1972-06-16 1981-04-28 Canada Packers, Limited Antiviral 5-(substituted benzal) hydantoins
US4013770A (en) * 1972-06-16 1977-03-22 Canada Packers Limited Antiviral 5-(substituted benzal) hydantoins
GB1601310A (en) * 1978-05-23 1981-10-28 Lilly Industries Ltd Aryl hydantoins
JPS5697277A (en) * 1980-01-07 1981-08-05 Takeda Chem Ind Ltd Thiazolidine derivative
DE3013626C2 (de) * 1980-04-09 1985-06-27 Degussa Ag, 6000 Frankfurt Verfahren zur Herstellung von 5-Arylidenhydantoinen (A)
DE3013647C2 (de) * 1980-04-09 1985-07-11 Degussa Ag, 6000 Frankfurt Verfahren zur Herstellung von 5-Arylidenhydantoinen (B)
JPS60233063A (ja) * 1984-05-02 1985-11-19 Showa Denko Kk ５−ベンジリデンヒダントインの製造法
US4582903A (en) * 1984-08-17 1986-04-15 Stauffer Chemical Company Synthesis of unsaturated hydantoins with an inexpensive catalyst
US4650876A (en) * 1984-08-17 1987-03-17 Stauffer Chemical Company Hydrogenation of substituted, unsaturated hydantoins to substituted, saturated hydantoins
PT83152B (pt) * 1985-08-09 1989-03-30 Lilly Co Eli Processo para a preparacao de compostos di-t-butilfenoicos
IE62214B1 (en) * 1988-05-25 1995-01-11 Warner Lambert Co Arylmethylenyl derivatives of thiazolidinones, imidazolidinones and oxazolidinones useful as antiallergy agents and antiinflammatory agents
US5306822A (en) * 1988-05-25 1994-04-26 Warner-Lambert Company Arylmethylenyl derivatives of oxazolidinone
US5208250A (en) * 1988-05-25 1993-05-04 Warner-Lambert Company Known and selected novel arylmethylenyl derivatives of thiazolidinones, imidazolidinones and oxazolidinones useful as antiallergy agents and anti-inflammatory agents
GB8911073D0 (en) * 1989-05-15 1989-06-28 Fujisawa Pharmaceutical Co New benzofuran derivatives,a process for the preparation thereof and pharmaceutical composition comprising the same
JPH1052765A (ja) 1996-08-09 1998-02-24 Sukematsu Iwashita 鉄筋材の圧接装置

Also Published As

Publication number Publication date
FI95129C (fi) 1995-12-27
NO924132L (no) 1992-12-23
EP0526598A1 (en) 1993-02-10
FI95129B (fi) 1995-09-15
EP0526598B1 (en) 1996-12-18
NO924132D0 (no) 1992-10-26
PT97507A (pt) 1992-01-31
JP2972377B2 (ja) 1999-11-08
CA2080917C (en) 2001-06-12
ATE146462T1 (de) 1997-01-15
FI924838A7 (fi) 1992-10-23
US5614541A (en) 1997-03-25
US5362733A (en) 1994-11-08
KR100207144B1 (en) 1999-07-15
US5889037A (en) 1999-03-30
JPH05331148A (ja) 1993-12-14
KR930700468A (ko) 1993-03-15
HUT65662A (en) 1994-07-28
CA2080917A1 (en) 1991-10-28
HU214872B (hu) 1998-07-28
LT3137B (en) 1995-01-31
DE69123738T2 (de) 1997-07-03
LV10097B (en) 1995-02-20
DE69123738D1 (en) 1997-01-30
HU9203369D0 (en) 1993-01-28
IE911430A1 (en) 1991-11-06
LV10097A (lv) 1994-05-10
AU646464B2 (en) 1994-02-24
AU7761891A (en) 1991-11-27
NO301928B1 (no) 1997-12-29
WO1991017151A1 (en) 1991-11-14
FI924838A0 (fi) 1992-10-23
PL166269B1 (pl) 1995-04-28
PT97507B (pt) 1998-08-31

Similar Documents

Publication Publication Date Title
LTIP227A (lt) Nauji farmakologiškai aktyvūs katecholio dariniai
ATE255106T1 (de) Bicyclische, heterocyclische sulfonamide und sulfonsäureester
AU2418188A (en) Therapeutic heterocyclic compounds
NO171680C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktiv morfolinoethylester av mycofenolsyre og derivater derav
DE68924681D1 (de) Heterocyclische Biphosphonsäurederivate.
NO166126C (no) Analogifremgangsmaate ved fremstilling av terapeutisk aktive kinolonkarboksylsyrederivater.
AU647904B2 (en) Novel nonsedative antihistaminics derived from benzimidazoles
RU95110762A (ru) Производные 5-гидразинохинолона, композиция для лечения или профилактики инфекционного заболевания, способ лечения или профилактики
FI914187A0 (fi) Menetelmä valmistaa kaavan /I/ mukaista 1-metyylikarbapeneemijohdosta
DE69725585D1 (de) Phenylalkylcarbonsäure-derivate
NO168243C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive alkansulfonanilid-derivater.
NO921159D0 (no) Tiazolidinon- og oksazolidinonderivater, fremgangsmaate til fremstilling derav, samt anvendelse av derivatene som vasodilatorer
AU6731100A (en) Integrase inhibitors containing aromatic heterocycle derivatives
EP0878196A4 (en) INHIBITORS OF KAINIC ACID NEUROTOXICITY AND PYRIDOTHIAZINE DERIVATIVES
ES2158290T3 (es) Derivados de tiazolidinona opticamente activos.
GEP19981300B (en) 1,8-benzonaphthyridine Derivatives, Method for its Production, Intermidiate Compositions and those Based on 1,8-Benzonaphthyridine Derivatives.
NO972731L (no) Thiazolidinonforbindelser og terapeutisk eller forhindrende middel mot angina pectoris omfattende forbindelsene som aktiv bestanddel
EP1197211A4 (en) CANCER PREVENTION AND TREATMENT ACTIVE INGREDIENTS
EP1142868A4 (en) AMIDE DERIVATIVES
DE59006477D1 (de) Fünfring-heterocyclisch anellierte Chinolinderivate.
DK0471856T3 (da) 15-Deoxyprostaglandin-derivater
EP0314432A3 (en) Fungicidal pyridyl sulphenyl carbamates
NO20004679L (no) Farmasøytisk sammensetning inneholdende en cystein- proteasehemmer for forebygging og terapi av hjernevevsforringelse
AU6982994A (en) Benzene derivative useful for ischemic diseases

Legal Events

Date Code Title Description
MM9A Lapsed patents

Effective date: 20021117